GILD vs MRNA
Gilead Sciences, Inc. and Moderna, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | GILD | MRNA |
|---|---|---|
| Revenue | $29.4B | $1.9B |
| Net income | $8.5B | $-2.8B |
| Gross margin | 78.8% | 55.3% |
| Net margin | 28.9% | −145.2% |
| Return on equity | 40.5% | −28.9% |
| Diluted EPS | $6.78 | −$7.26 |
| Dividend / share | $3.16 | · |
| Payout ratio | 47.0% | · |
| Free cash flow | $9.5B | $-2.1B |
| Equity | $22.7B | $8.7B |
| Net debt / equity | 0.77× | −0.23× |
| Current ratio | 1.55× | 3.29× |
| Revenue CAGR 5y | 3.6% | 19.3% |
| Profit CAGR 5y | 133.3% | · |
GILD bills 15.1× the revenue of MRNA, and MRNA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | GILD | MRNA |
|---|---|---|
| FY2025 | $29.4B | $1.9B |
| FY2024 | $28.8B | $3.2B |
| FY2023 | $27.1B | $6.8B |
| FY2022 | $27.3B | $19.3B |
| FY2021 | $27.3B | $18.5B |
| FY2020 | $24.7B | $803.0M |
| FY2019 | $22.4B | $60.0M |
| FY2018 | $22.1B | $135.1M |
| FY2017 | $26.1B | $205.8M |
| FY2016 | $30.4B | $108.4M |
Bottom line
| Fiscal year | GILD | MRNA |
|---|---|---|
| FY2025 | $8.5B | $-2.8B |
| FY2024 | $480.0M | $-3.6B |
| FY2023 | $5.7B | $-4.7B |
| FY2022 | $4.6B | $8.4B |
| FY2021 | $6.2B | $12.2B |
| FY2020 | $123.0M | $-747.0M |
| FY2019 | $5.4B | $-514.0M |
| FY2018 | $5.5B | $-384.7M |
| FY2017 | $4.6B | $-255.9M |
| FY2016 | $13.5B | $-216.2M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$27,499,000,000 | GILD |
| FY2024 | +$25,518,000,000 | GILD |
| FY2023 | +$20,268,000,000 | GILD |
| FY2022 | +$8,018,000,000 | GILD |
| FY2021 | +$8,834,000,000 | GILD |
| FY2020 | +$23,886,000,000 | GILD |
| FY2019 | +$22,389,000,000 | GILD |
| FY2018 | +$21,991,932,000 | GILD |
| FY2017 | +$25,901,175,000 | GILD |
| FY2016 | +$30,281,604,000 | GILD |
GILD has reported the higher revenue in every one of these 10 fiscal years. The gap has narrowed since the earliest year compared.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +174.1 pp | GILD |
| FY2024 | +111.7 pp | GILD |
| FY2023 | +89.5 pp | GILD |
| FY2022 | −26.7 pp | MRNA |
| FY2020 | +93.4 pp | GILD |
| FY2019 | +880.6 pp | GILD |
| FY2018 | +309.5 pp | GILD |
| FY2017 | +142.1 pp | GILD |
| FY2016 | +243.8 pp | GILD |
The higher net margin has changed hands between GILD and MRNA over this period.
9 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's net margin has been more volatile than GILD's over the 9 comparable fiscal years — 245.6 percentage points of standard deviation against 12.7.
9 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between GILD and MRNA over these 9 fiscal years — GILD led in 8 and MRNA in 1.
9 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's return on equity has been more volatile than GILD's over the 7 comparable fiscal years — 64.6 percentage points of standard deviation against 13.6.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between GILD and MRNA over these 7 fiscal years — GILD led in 5 and MRNA in 2.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.